Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rein Therapeutics (RNTX) Other Operating Expenses (2016 - 2024)

Rein Therapeutics (RNTX) has disclosed Other Operating Expenses for 2 consecutive years, with $37.0 million as the latest value for Q4 2024.

  • On a quarterly basis, Other Operating Expenses changed N/A to $37.0 million in Q4 2024 year-over-year; TTM through Sep 2025 was $37.0 million, a N/A change, with the full-year FY2024 number at $37.0 million, up 231.06% from a year prior.
  • Other Operating Expenses was $37.0 million for Q4 2024 at Rein Therapeutics, up from $2.0 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $37.0 million in Q4 2024 to a low of $37.0 million in Q4 2024.